EXEL  valuation analysis

Name: Exelixis Inc
Description: Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. (more)
Industry: Biotechnology
Last 10Q10Qs are quarterly reports which contain a company's financial figures. We use these to calculate the FFER.: May 10, 2022
Market cap: $5.76B (631st)
Sales(TTM): $1.52B (907th)
Earnings(TTM): $298.04M (664th)

FFER: 0.79*
Actual price: $17.81
* Earnings were reported Aug 03, 2022 but we do not have the financials for this quarter. This is likely because the company has not yet released them. However, it might also be a problem with data quality. Regardless, you should take the FFER above with a grain of salt until we get updated financials.

Prices as of EOD 2022-05-25
Price & Estimates
Sales & Earnings history (TTM)
  • Exelixis Inc's operating income grew by 611.4% ($52.64M to $374.52M) over one year against a market average growth of 174.4%.
Earnings / MarketCap
Exelixis Inc
"Biotechnology" industry
Sales / MarketCap
Exelixis Inc
"Biotechnology" industry
Book / MarketCap
Exelixis Inc
"Biotechnology" industry
Equity / Assets
Exelixis Inc
"Biotechnology" industry